Gennex Laboratories Limited has fulfilled its quarterly regulatory obligations by submitting the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

Regulatory Submission Details

The pharmaceutical company submitted the compliance certificate to multiple stock exchanges on April 13, 2026. The submission was addressed to three major exchanges where the company's securities are listed:

Certificate Confirmation

R&D Infotech Private Limited, serving as the company's registrar and transfer agent, issued the certificate on April 06, 2026. The certificate confirms several key compliance aspects:

• Securities received from depository participants for dematerialisation during the quarter were properly confirmed to the depositories
• All securities comprised in the certificates have been listed on stock exchanges where previously issued securities are traded
• Security certificates received for dematerialisation were mutilated and cancelled after due verification
• Names of depositories were substituted in the register of members as registered owners within the mandated 15-day period

Company Authorization

The submission was authorized by Dinesh Kumar Kejriwal, Company Secretary (Membership # A/19293), who digitally signed the documents on April 13, 2026. The certificate was signed by Ratan Kumar Mishra on behalf of R&D Infotech Private Limited.

Regulatory Context

This quarterly submission represents standard compliance with SEBI regulations governing depositories and participants. The regulation ensures proper handling and processing of securities during the dematerialisation process, maintaining transparency and investor protection in the securities market.

Gennex Laboratories operates from its office in Hyderabad and maintains manufacturing facilities in Telangana. The company continues to meet its regulatory obligations across multiple stock exchanges where its securities are listed.

Gennex laboratories Limited has scheduled a board meeting for April 16, 2026, to deliberate on matters related to an upcoming Extraordinary General Meeting (EGM). The pharmaceutical company informed stock exchanges about this development through a regulatory filing dated April 08, 2026.

Meeting Details and Agenda

The board meeting will be conducted on Thursday, April 16, 2026 at 04.00 P.M. at the company's corporate office located at Akash Ganga, Plot 144, Srinagar Colony, Hyderabad, Telangana, 500073. The meeting has been convened in compliance with Regulation 29 of SEBI (LODR) Regulations, 2015.

Key Agenda Items

The board will primarily focus on three significant matters during the meeting:

• Director Regularization: To decide regarding the conduct of Extraordinary General Meeting for regularization of Additional Director Ms. Khushbu Kachhawa (DIN: 10872432) as a Director (Non-Executive Independent Woman Director) of the Company
• Scrutinizer Appointment: To consider and appoint scrutinizer of the Extraordinary General Meeting in case of finalization of the date of EGM
• Additional Business: Any other business with permission of the Chairperson

Regulatory Compliance and Communication

Gennex Laboratories Limited has communicated this development to multiple stock exchanges where its shares are listed. The company has informed BSE Limited (Script Code: 531739), The Ahmedabad Stock Exchange Limited, and The Calcutta Stock Exchange Limited (Script Code: 26178) about the scheduled board meeting.

The intimation has also been uploaded on the company's official website at www.gennexlab.com , ensuring transparency and accessibility for all stakeholders. Company Secretary & Compliance Officer Dinesh Kumar Kejriwal (Membership #A19293) has signed the regulatory filing, which was digitally authenticated on April 08, 2026.